Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oteseconazole (Primary)
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Acronyms RENOVATE
  • Sponsors Viamet Pharmaceuticals

    • Most Recent Events

    • 18 May 2020 Results published in the British Journal of Dermatology
    • 27 Jul 2017 According to a Viamet Pharmaceuticals media release, results from this trial will be presented at the American Podiatric Medical Association (APMA) 2017 Annual Scientific Meeting (The National).
    • 21 Jun 2017 According to a Viamet Pharmaceuticals media release, data from this trial will be presented at the 4th International Summit on Nail Diseases 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top